Does the media favor AVXL or MGTX?

In the previous week, MeiraGTx had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 6 mentions for MeiraGTx and 4 mentions for Anavex Life Sciences. MeiraGTx's average media sentiment score of 0.74 beat Anavex Life Sciences' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AVXL or WVE?

In the previous week, Anavex Life Sciences had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 4 mentions for Anavex Life Sciences and 2 mentions for WAVE Life Sciences. Anavex Life Sciences' average media sentiment score of 0.00 beat WAVE Life Sciences' score of -0.97 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Which has higher valuation & earnings, AVXL or SVRA?

Savara is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anavex Life Sciences N/A N/A -$46.38M -$0.39 N/A Savara N/A N/A -$118.84M -$0.58 N/A

Is AVXL or SVRA more profitable?

Anavex Life Sciences' return on equity of -32.73% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -32.73% -30.15% Savara N/A -90.28% -68.95%

Does the media favor AVXL or SVRA?

In the previous week, Anavex Life Sciences had 3 more articles in the media than Savara. MarketBeat recorded 4 mentions for Anavex Life Sciences and 1 mentions for Savara. Anavex Life Sciences' average media sentiment score of 0.00 beat Savara's score of -0.60 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Which has stronger valuation & earnings, AVXL or CRVS?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anavex Life Sciences N/A N/A -$46.38M -$0.39 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A

Is AVXL or CRVS more profitable?

Anavex Life Sciences' return on equity of -32.73% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -32.73% -30.15% Corvus Pharmaceuticals N/A -36.15% -33.62%

Does the media refer more to AVXL or CRVS?

In the previous week, Anavex Life Sciences had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 4 mentions for Anavex Life Sciences and 3 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.20 beat Anavex Life Sciences' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corvus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALVO or AVXL?

In the previous week, Alvotech had 15 more articles in the media than Anavex Life Sciences. MarketBeat recorded 19 mentions for Alvotech and 4 mentions for Anavex Life Sciences. Alvotech's average media sentiment score of 0.16 beat Anavex Life Sciences' score of 0.00 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 3 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Anavex Life Sciences (AVXL) Competitors

$3.24 +0.11 (+3.51%)

As of 08/21/2026 04:00 PM Eastern

Compare

AVXL vs. MGTX, WVE, SVRA, CRVS, and ALVO

Should you buy Anavex Life Sciences stock or one of its competitors? Anavex Life Sciences's main competitors and comparable companies include MeiraGTx (MGTX), WAVE Life Sciences (WVE), Savara (SVRA), Corvus Pharmaceuticals (CRVS), and Alvotech (ALVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anavex Life Sciences compare to MeiraGTx?

Anavex Life Sciences (NASDAQ:AVXL) and MeiraGTx (NASDAQ:MGTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Anavex Life Sciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

Anavex Life Sciences has higher earnings, but lower revenue than MeiraGTx. Anavex Life Sciences is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A
MeiraGTx	$81.39M	16.92	-$114.20M	$0.71	20.20

In the previous week, MeiraGTx had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 6 mentions for MeiraGTx and 4 mentions for Anavex Life Sciences. MeiraGTx's average media sentiment score of 0.74 beat Anavex Life Sciences' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anavex Life Sciences presently has a consensus target price of $21.33, indicating a potential upside of 558.44%. MeiraGTx has a consensus target price of $26.17, indicating a potential upside of 82.47%. Given Anavex Life Sciences' higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MeiraGTx	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

MeiraGTx has a net margin of 19.87% compared to Anavex Life Sciences' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-32.73%	-30.15%
MeiraGTx	19.87%	283.85%	29.39%

31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 11.4% of Anavex Life Sciences shares are held by company insiders. Comparatively, 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

MeiraGTx beats Anavex Life Sciences on 13 of the 16 factors compared between the two stocks.

How does Anavex Life Sciences compare to WAVE Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Anavex Life Sciences presently has a consensus target price of $21.33, suggesting a potential upside of 558.44%. WAVE Life Sciences has a consensus target price of $22.53, suggesting a potential upside of 325.89%. Given Anavex Life Sciences' higher probable upside, research analysts plainly believe Anavex Life Sciences is more favorable than WAVE Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Anavex Life Sciences has higher earnings, but lower revenue than WAVE Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A
WAVE Life Sciences	$42.73M	24.39	-$204.38M	-$1.09	N/A

In the previous week, Anavex Life Sciences had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 4 mentions for Anavex Life Sciences and 2 mentions for WAVE Life Sciences. Anavex Life Sciences' average media sentiment score of 0.00 beat WAVE Life Sciences' score of -0.97 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Anavex Life Sciences has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, indicating that its share price is 226% less volatile than the broader market.

Anavex Life Sciences has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. Anavex Life Sciences' return on equity of -32.73% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-32.73%	-30.15%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

Summary

Anavex Life Sciences beats WAVE Life Sciences on 9 of the 15 factors compared between the two stocks.

How does Anavex Life Sciences compare to Savara?

Anavex Life Sciences (NASDAQ:AVXL) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Anavex Life Sciences' return on equity of -32.73% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-32.73%	-30.15%
Savara	N/A	-90.28%	-68.95%

Savara is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

In the previous week, Anavex Life Sciences had 3 more articles in the media than Savara. MarketBeat recorded 4 mentions for Anavex Life Sciences and 1 mentions for Savara. Anavex Life Sciences' average media sentiment score of 0.00 beat Savara's score of -0.60 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Anavex Life Sciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Savara has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 11.4% of Anavex Life Sciences shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Anavex Life Sciences presently has a consensus price target of $21.33, indicating a potential upside of 558.44%. Savara has a consensus price target of $10.14, indicating a potential upside of 81.45%. Given Anavex Life Sciences' higher probable upside, research analysts plainly believe Anavex Life Sciences is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Anavex Life Sciences beats Savara on 10 of the 14 factors compared between the two stocks.

How does Anavex Life Sciences compare to Corvus Pharmaceuticals?

Anavex Life Sciences (NASDAQ:AVXL) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Anavex Life Sciences presently has a consensus price target of $21.33, suggesting a potential upside of 558.44%. Corvus Pharmaceuticals has a consensus price target of $33.33, suggesting a potential upside of 130.52%. Given Anavex Life Sciences' higher probable upside, equities analysts plainly believe Anavex Life Sciences is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Anavex Life Sciences had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 4 mentions for Anavex Life Sciences and 3 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.20 beat Anavex Life Sciences' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anavex Life Sciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

Anavex Life Sciences' return on equity of -32.73% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-32.73%	-30.15%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Summary

Anavex Life Sciences and Corvus Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Anavex Life Sciences compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Alvotech had 15 more articles in the media than Anavex Life Sciences. MarketBeat recorded 19 mentions for Alvotech and 4 mentions for Anavex Life Sciences. Alvotech's average media sentiment score of 0.16 beat Anavex Life Sciences' score of 0.00 indicating that Alvotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	3 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alvotech has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

Alvotech has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	2.27	$27.92M	-$0.61	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A

Anavex Life Sciences has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of -11.92% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-36.31%	-11.92%	-11.73%
Anavex Life Sciences	N/A	-32.73%	-30.15%

Alvotech currently has a consensus target price of $7.60, suggesting a potential upside of 71.56%. Anavex Life Sciences has a consensus target price of $21.33, suggesting a potential upside of 558.44%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.14
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

31.6% of Anavex Life Sciences shares are owned by institutional investors. 0.5% of Alvotech shares are owned by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Alvotech and Anavex Life Sciences tied by winning 7 of the 14 factors compared between the two stocks.

Get Anavex Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVXL vs. The Competition

Export

Metric	Anavex Life Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$300.34M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-8.31	11.62	272.60	24.24
Price / Sales	N/A	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	2.95	16.80	13.05	6.20
Net Income	-$46.38M	-$12.50M	$3.47B	$348.59M
7 Day Performance	0.62%	3.29%	2.09%	0.08%
1 Month Performance	30.65%	8.23%	6.64%	3.88%
1 Year Performance	-66.00%	55.05%	25.02%	16.98%

Anavex Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVXL Anavex Life Sciences	1.1579 of 5 stars	$3.24 +3.5%	$21.33 +558.4%	-66.0%	$300.34M	N/A	N/A	40	Upcoming Earnings
MGTX MeiraGTx	4.1797 of 5 stars	$13.02 -0.4%	$26.00 +99.7%	+83.1%	$1.21B	$81.39M	N/A	300	Insider Trade Gap Up
WVE WAVE Life Sciences	2.7746 of 5 stars	$6.07 -0.5%	$22.53 +271.2%	-47.9%	$1.20B	$42.73M	N/A	240	Analyst Downgrade
SVRA Savara	1.8071 of 5 stars	$5.73 -1.7%	$10.14 +77.0%	+76.9%	$1.19B	N/A	N/A	20
CRVS Corvus Pharmaceuticals	2.8507 of 5 stars	$13.74 -1.3%	$33.33 +142.6%	+160.5%	$1.17B	N/A	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVXL) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anavex Life Sciences (AVXL) Competitors

AVXL vs. MGTX, WVE, SVRA, CRVS, and ALVO

How does Anavex Life Sciences compare to MeiraGTx?

Summary

How does Anavex Life Sciences compare to WAVE Life Sciences?

Summary

How does Anavex Life Sciences compare to Savara?

Summary

How does Anavex Life Sciences compare to Corvus Pharmaceuticals?

Summary

How does Anavex Life Sciences compare to Alvotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anavex Life Sciences (AVXL) Competitors

AVXL vs. MGTX, WVE, SVRA, CRVS, and ALVO

How does Anavex Life Sciences compare to MeiraGTx?

Which has more risk & volatility, AVXL or MGTX?

Which has preferable earnings and valuation, AVXL or MGTX?

Does the media favor AVXL or MGTX?

Do analysts recommend AVXL or MGTX?

Is AVXL or MGTX more profitable?

Do insiders & institutionals believe in AVXL or MGTX?

Summary

How does Anavex Life Sciences compare to WAVE Life Sciences?

Do analysts rate AVXL or WVE?

Which has better earnings & valuation, AVXL or WVE?

Does the media refer more to AVXL or WVE?

Do insiders and institutionals hold more shares of AVXL or WVE?

Which has more risk & volatility, AVXL or WVE?

Is AVXL or WVE more profitable?

Summary

How does Anavex Life Sciences compare to Savara?

Is AVXL or SVRA more profitable?

Which has higher valuation & earnings, AVXL or SVRA?

Does the media favor AVXL or SVRA?

Which has more risk & volatility, AVXL or SVRA?

Do institutionals and insiders believe in AVXL or SVRA?

Do analysts prefer AVXL or SVRA?

Summary

How does Anavex Life Sciences compare to Corvus Pharmaceuticals?

Do analysts prefer AVXL or CRVS?

Does the media refer more to AVXL or CRVS?

Do institutionals & insiders hold more shares of AVXL or CRVS?

Which has more risk and volatility, AVXL or CRVS?

Which has stronger valuation & earnings, AVXL or CRVS?

Is AVXL or CRVS more profitable?

Summary

How does Anavex Life Sciences compare to Alvotech?

Does the media prefer ALVO or AVXL?

Which has more risk and volatility, ALVO or AVXL?

Which has preferable valuation and earnings, ALVO or AVXL?

Is ALVO or AVXL more profitable?

Do analysts recommend ALVO or AVXL?

Do institutionals and insiders have more ownership in ALVO or AVXL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools